During this time, the body adapts to the medication, eating patterns begin to shift, and measurable changes in weight typically occur
And on April 1, the Food and Drug Administration (FDA) approved Foundayo (orforglipron), a pill for adults with obesity or who are overweight and have a weight-related medical condition
In 2023, Juan P Frias and colleagues, in The Lancet, published the first phase two clinical trial of orforglipron, which investigated the use of a small-molecule oral GLP-1R agonist called orforglipron in type 2 diabetes, which can be taken at any time of the day without restrictions on food and water intake (Frias et al., 2023)
[DOI] [PMC free article] [PubMed] [Google Scholar] 205.Zhang W., Zhang J
Compounded Semaglutide is generally well-tolerated but in some users, it could lead to mild side effects like nausea, lightheadedness, vomiting, stomach upset, or constipation
Its triple-hormone mechanism, impressive clinical trial outcomes, and potential to deliver substantial weight loss have positioned it as a possible next-generation treatment for obesity and metabolic disease